Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.44)
# 322
Out of 5,124 analysts
237
Total ratings
45.58%
Success rate
28.68%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.28 | +1.58% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $17.90 | +168.16% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $10.18 | +135.76% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $10.20 | +86.27% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $8.57 | +180.05% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $47.55 | -20.08% | 9 | Nov 5, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $132 → $153 | $79.50 | +92.45% | 9 | Oct 17, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $50.00 | +26.00% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $23.53 | +239.99% | 10 | Sep 25, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $105 | $23.30 | +350.64% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $78.68 | +49.97% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $63.30 | +16.90% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $11 | $7.39 | +48.85% | 1 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $5.71 | +180.21% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $26.40 | +13.64% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $22.49 | +260.16% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $5.53 | +26.58% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $46.30 | +165.66% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $4.02 | +2,138.81% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.40 | +1,645.20% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $18.45 | +35.50% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $27.59 | +142.84% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $6.00 | +183.33% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.79 | +111.08% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.71 | +543.27% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.19 | +246.82% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.11 | +1,161.26% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.16 | +1,020.69% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.47 | +1,328.57% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.80 | +233.33% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.56 | +3,449.88% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $5.60 | +310.71% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.09 | +82,468.81% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $21.84 | +1,731.50% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.09 | +3,966.99% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.76 | +2,562.72% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.83 | +9,721.04% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.63 | +574.85% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.99 | +2,915.08% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.15 | +7,726.09% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.83 | +303,514.46% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $2.22 | +136,843.11% | 1 | Jan 9, 2020 |
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.28
Upside: +1.58%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $17.90
Upside: +168.16%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $10.18
Upside: +135.76%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $10.20
Upside: +86.27%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $8.57
Upside: +180.05%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $47.55
Upside: -20.08%
Disc Medicine
Oct 17, 2025
Maintains: Overweight
Price Target: $132 → $153
Current: $79.50
Upside: +92.45%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $50.00
Upside: +26.00%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $23.53
Upside: +239.99%
Ultragenyx Pharmaceutical
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $23.30
Upside: +350.64%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $78.68
Upside: +49.97%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $63.30
Upside: +16.90%
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $7.39
Upside: +48.85%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $5.71
Upside: +180.21%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $26.40
Upside: +13.64%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $22.49
Upside: +260.16%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $5.53
Upside: +26.58%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $46.30
Upside: +165.66%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $4.02
Upside: +2,138.81%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.40
Upside: +1,645.20%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $18.45
Upside: +35.50%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $27.59
Upside: +142.84%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $6.00
Upside: +183.33%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $3.79
Upside: +111.08%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.71
Upside: +543.27%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.19
Upside: +246.82%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.11
Upside: +1,161.26%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.16
Upside: +1,020.69%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.47
Upside: +1,328.57%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.80
Upside: +233.33%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.56
Upside: +3,449.88%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $5.60
Upside: +310.71%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.09
Upside: +82,468.81%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $21.84
Upside: +1,731.50%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.09
Upside: +3,966.99%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.76
Upside: +2,562.72%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.83
Upside: +9,721.04%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.63
Upside: +574.85%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.99
Upside: +2,915.08%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.15
Upside: +7,726.09%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.83
Upside: +303,514.46%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $2.22
Upside: +136,843.11%